M. DiBartolomeo

1 ta ish

Fondazione IRCCS Istituto Nazionale dei Tumori

1. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

   Eric Van Cutsem, Fernando Rivera, Scott Berry +9

   MaqolaOAOchiq kirish20092 iqtibos

   ABIABI:AkademIndex/2026.other.237787